
Opinion|Videos|August 2, 2024
Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
Author(s)Jason Fangusaro, MD
The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.
Advertisement
Episodes in this series

- What are some ongoing Phase II/III trials in this space?
- Phase II Vinblastine +/- Bevacizumab in chemotherapy naïve pLGG (
NCT02840409 ) - Phase III ACNS1831: Selumetinib vs carboplatin/vincristine in NF1 pLGG (
NCT03871257 ) - Phase III ACNS1833: Selumetinib vs carboplatin/vincristine in non-V600E and non-NF1 pLGG (
NCT04166409 )
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


